Rocket Pharmaceuticals said that the first patient has received investigational therapy in the open-label, Phase 1 clinical trial of RP-L301, the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Pyruvate Kinase Deficiency (PKD), a rare monogenic red blood cell disorder.
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study.
Russia's Sechenov First Moscow State Medical University (Sechenov University) has reportedly completed clinical trials of a coronavirus vaccine candidate developed by Gamaleya Research Institute of Epidemiology and Microbiology.
Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that it has completed enrollment for both cohorts of the Phase 2 study of its vaccine candidate (mRNA-1273) against Covid-19.
Clinical-stage biopharmaceutical firm Corvus Pharmaceuticals has commenced the phase 1 clinical study of novel Immunotherapy for patients with Covid-19 disease.
AVROBIO announced that the first patient has been dosed in the company’s GuardOne clinical trial, a Phase 1/2 investigational study evaluating AVR-RD-02 for Gaucher disease type 1.
Sunovion Pharmaceuticals said that a phase 2 study evaluating SEP-4199 as the treatment of major depressive episodes associated with bipolar I disorder (bipolar I depression) failed to meet its primary endpoint.
Sinovac Biotech ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced an update to its previously announced partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines.
Regeneron Pharmaceuticals has announced the commencement of Phase 3 trial with its investigational double-antibody cocktail REGN-COV2 to treat and prevent Covid-19 disease.
Idorsia announced positive top-line results of the second pivotal Phase 3 study investigating 10 and 25 mg doses of its dual orexin receptor antagonist, daridorexant, in 924 adult and elderly patients (39.3% ≥ 65 years) with insomnia.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.